Is TB-500 Legal in South Carolina?

The Federal Framework That Controls TB-500 Access Everywhere in the U.S.

South Carolina does not operate in isolation on peptide law. Federal rules set the floor, and they govern what any licensed pharmacy or prescriber in the state can legally do with TB-500.

What the FDA Says About Compounded Peptides

The Federal Food, Drug, and Cosmetic Act (FDCA) permits licensed pharmacies to compound medications for individual patients under Section 503A, and permits outsourcing facilities to compound larger batches under Section 503B. Both pathways require that any non-FDA-approved active ingredient appear on an FDA-maintained list of bulk drug substances before it can be used in a compounded preparation intended for human use. Section 503A bulk substances are governed under 21 U.S.C. §353a.

TB-500, the synthetic peptide derived from thymosin beta-4, was nominated for the 503A Category 1 list. FDA evaluated it and declined to include it. That decision, finalized through agency guidance updates in 2023, means no 503A pharmacy in any state, including South Carolina, may lawfully compound TB-500 for human patients. FDA's current 503A bulk substances lists are published on FDA.gov.

The 503B Outsourcing Pathway

Section 503B outsourcing facilities operate under even stricter rules than 503A pharmacies. They must use only substances on FDA's 503B-specific bulk list or substances that are components of an FDA-approved drug. TB-500 appears on neither list. FDA maintains the 503B bulk list here. No 503B facility in South Carolina or elsewhere may legally produce TB-500 for human administration.

Why "Not Scheduled" Does Not Mean "Legal to Prescribe"

TB-500 is not listed in any schedule of the Controlled Substances Act (CSA). That fact sometimes leads patients to assume it is freely legal. It is not. A substance can be outside the CSA and still be unlawful to compound, sell, or administer as a drug under the FDCA. FDA's authority over new drugs is separate from DEA scheduling. Any product intended to treat, cure, mitigate, or prevent a disease in humans is a "drug" under 21 U.S.C. §321(g)(1), and it must either hold an approved NDA/ANDA or qualify for a compounding exemption. TB-500 satisfies neither condition right now. See FDA's definition of "drug" and new drug requirements.

South Carolina State Law: What Exists and What Does Not

South Carolina has its own pharmacy practice act and medical practice act, but neither creates an independent framework for individual peptides that differs from federal law.

South Carolina Board of Pharmacy

The South Carolina Board of Pharmacy (SCBOP) licenses pharmacies operating within the state. Compounding pharmacies in South Carolina must comply with USP <797> sterile compounding standards and are also subject to oversight from SCBOP. Critically, SCBOP does not publish a separate "permitted peptide" list that supersedes FDA bulk substance decisions. A pharmacy operating in South Carolina that compounds TB-500 for human use would be violating federal FDCA provisions, and SCBOP could take action against that pharmacy's state license as well. USP <797> sterile compounding guidelines are described by FDA here.

South Carolina Medical Practice Act

Licensed physicians in South Carolina practice under Title 40, Chapter 47 of the South Carolina Code of Laws. Nothing in that chapter specifically mentions TB-500 or thymosin beta-4. A physician who prescribes a drug that cannot be lawfully compounded or dispensed risks professional discipline under the state medical board's standards of care provisions, even if no targeted state statute addresses the specific substance. Writing a prescription for TB-500 as a human drug today carries real regulatory risk for any South Carolina provider.

No Explicit State Ban, Either

South Carolina has not passed legislation that independently bans TB-500. This matters for the "research chemical" pathway discussed below. There is no state-level criminal statute making simple possession of TB-500 by an individual consumer a crime in South Carolina, separate from any federal misbranding allegation that would attach to the seller rather than the buyer. The legal exposure sits primarily with whoever manufactures, labels, or sells the product as a human drug, not with a private individual who purchases it for non-human or personal research use. This area is unsettled, and patients should not interpret "no explicit ban" as legal clearance.

The Research Chemical Gray Zone

TB-500 is widely sold online as a "research chemical" labeled "not for human use." This labeling convention is the supplier's attempt to avoid FDA drug regulations.

How Research Chemical Sales Work

Vendors sell TB-500 in lyophilized powder vials, typically 2 mg to 10 mg per vial, with disclaimers that the product is for laboratory or in-vitro research only. Federal law does not prohibit the sale of a chemical substance for legitimate research purposes. The legal exposure emerges when a vendor knows, or has reason to know, that a buyer intends to use the product for human self-administration. At that point, the product meets the definition of a misbranded or unapproved new drug. FDA's guidance on research chemicals and unapproved drugs is available here.

Quality and Safety Risks

Research-chemical TB-500 is not manufactured under FDA Current Good Manufacturing Practice (cGMP) regulations. Independent third-party testing of peptide research chemicals has repeatedly found contamination, incorrect concentrations, and bacterial endotoxins. A 2021 analysis published in the context of peptide purity research identified significant batch-to-batch variability in compounded and research-grade peptide products. Injecting a non-sterile, non-cGMP product carries risks of localized infection, systemic infection, and immune reactions that cannot be quantified without sterility testing data. Patients in South Carolina who self-administer research-chemical TB-500 are accepting unknown quality risk with no physician oversight and no legal compounding supply chain behind the product.

What the Science Says About TB-500

Understanding why patients want TB-500 requires looking at the biology. Thymosin beta-4 is an endogenous 43-amino-acid peptide involved in actin sequestration, cell migration, and tissue repair signaling. The synthetic fragment most commonly sold as TB-500 is the tetrapeptide Ac-SDKP (N-acetyl-seryl-aspartyl-lysyl-proline), although some vendors sell the full-length thymosin beta-4.

Preclinical Evidence

Animal studies have shown thymosin beta-4 promotes wound healing, reduces cardiac fibrosis after infarction, and accelerates muscle repair. A 2010 study in the Journal of Molecular and Cellular Cardiology (RegeneRx-sponsored) demonstrated improved cardiac function in a rat infarction model after thymosin beta-4 administration. That study line is contextualized in PubMed-indexed literature accessible here.

Human Clinical Data Is Limited

Human trials of thymosin beta-4 have been conducted, primarily by RegeneRx Biopharmaceuticals. A Phase 2 trial (RGN-352) evaluated intravenous thymosin beta-4 in patients after acute myocardial infarction. The trial did not demonstrate statistically significant improvement in the primary endpoint. A separate Phase 2 trial of topical thymosin beta-4 (RGN-259) for dry eye disease showed some symptom improvement in a subset of patients. None of these trials used the "TB-500" research chemical formulation, and none resulted in FDA approval. PubMed search for thymosin beta-4 clinical trials. The absence of an approved NDA is precisely why TB-500 cannot be prescribed through a standard pharmacy today.

Athletic and Recovery Use Context

TB-500 appears on the World Anti-Doping Agency (WADA) Prohibited List under Section S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics). WADA's prohibited list is published at wada-ama.org. Any competitive athlete subject to WADA or USADA testing in South Carolina who uses TB-500, regardless of legal status, risks a doping violation.

How Thymosin Beta-4 Differs from Other Peptides With Legal Access

Not all peptides share TB-500's current regulatory status. Understanding the contrast helps clarify what "legal peptide therapy" actually looks like in South Carolina.

Peptides Currently Accessible Through Compounding

Several peptides remain on FDA's 503A bulk substances list or have received some form of regulatory acknowledgment that permits compounding. Sermorelin, for example, is a GHRH analogue that was previously FDA-approved as Geref and retains a clear pathway for compounding in many contexts. BPC-157 has a similarly contested status to TB-500 and was removed from the 503A nominee list as well. PT-141 (bremelanotide) received FDA approval as Vyleesi in 2019 and can be prescribed by brand. FDA's approved drug database is searchable at accessdata.fda.gov.

The Pathway That Would Change TB-500's Status

If a sponsor submitted a full NDA for thymosin beta-4 and received approval, or if FDA re-evaluated the bulk substance nomination and added TB-500 to the Category 1 list, the compounding pathway would reopen. As of the date of this article's last review (July 2025), neither has occurred. RegeneRx's IND-stage programs have not advanced to NDA filing. FDA's drug development pipeline information is available via clinicaltrials.gov and FDA.gov.

HealthRX TB-500 Legal Status Decision Framework (South Carolina)

| Scenario | Legal Status | Recommended Action | |---|---|---| | Patient wants TB-500 from a licensed SC compounding pharmacy | Not lawful. FDA bulk ban in effect. | Discuss alternative peptides with 503A access. | | Patient wants a prescription from a SC physician | No valid Rx pathway. No approved NDA or active compounding permission. | Physician should decline and document reason. | | Patient purchases research-chemical TB-500 for self-administration | Federal gray zone. No SC state criminal statute, but FDA misbranding rules apply to seller. | Advise patient of quality and regulatory risks. | | Competitive athlete in SC wants to use TB-500 | WADA/USADA prohibited. Doping violation risk regardless of local law. | Do not use if subject to drug testing. | | Patient seeks thymosin beta-4 through a clinical trial | Potentially lawful under active IND. Check clinicaltrials.gov for open studies. | Refer to ClinicalTrials.gov for enrollment options. |

Enforcement Field: Who Gets Targeted and How

Federal enforcement of peptide regulations has focused almost entirely on manufacturers, distributors, and compounding pharmacies, not individual patients. FDA warning letters sent to peptide vendors between 2020 and 2024 targeted companies selling BPC-157, TB-500, and other unapproved peptides with drug claims. FDA warning letters are publicly available at FDA.gov.

Individual consumers in South Carolina who possess TB-500 for personal use have not been the subject of reported federal prosecutions in publicly available court records. That asymmetry does not eliminate risk. It reflects current enforcement priorities, which can shift. Any individual who purchases TB-500 from a vendor making explicit drug claims is participating in a transaction that involves a misbranded drug on the seller's end.

South Carolina law enforcement has not issued separate guidance targeting TB-500 possession. The state attorney general's office has not published opinions on thymosin beta-4. In the absence of targeted state action, the practical risk to an individual consumer in South Carolina remains low, but the legal status is not clean.

Practical Guidance for South Carolina Patients and Providers

Patients who come to a HealthRX provider asking about TB-500 deserve a straightforward answer, not vague reassurance.

What Providers Should Do Now

A South Carolina physician who receives a patient request for TB-500 should document that the substance is not available through a lawful compounding pathway under current federal rules. The provider should discuss the patient's underlying goal, whether that is injury recovery, inflammation management, or another indication, and identify whether any FDA-approved or lawfully compounded alternative exists. Sermorelin, for example, addresses some recovery-adjacent goals through a legal pathway. FDA-approved drugs can be searched at accessdata.fda.gov.

The American Association of Clinical Endocrinology (AACE) position on compounded peptides states that providers should use "only those compounded preparations that comply with applicable FDA and state pharmacy board regulations." AACE clinical practice guidelines are available at aace.com. Writing a prescription for TB-500 as things stand today does not comply with those regulations.

What Patients Should Know Before Buying Online

Patients who choose to purchase TB-500 as a research chemical despite this guidance should understand three specific risks. First, product purity is not guaranteed and no recall mechanism exists for non-cGMP products. Second, self-injection of a non-sterile product in a non-clinical setting carries infection risk that is not covered by standard health insurance. Third, any online vendor making therapeutic claims about TB-500 is selling a misbranded drug under federal law, regardless of the "research only" label on the vial.

Monitoring the Regulatory Situation

The FDA bulk substances list is a living document. The agency accepts new nominations and re-evaluates existing ones. Patients and providers who want to track whether TB-500 regains a compounding pathway should monitor FDA's human drug compounding page for updates to the 503A and 503B bulk substance lists. As of July 2025, TB-500 remains off both lists.